Analysts Set Affimed (NASDAQ:AFMD) PT at $41.67

Affimed (NASDAQ:AFMD) has been assigned an average recommendation of “Buy” from the six research firms that are covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $41.67.

AFMD has been the subject of a number of research analyst reports. Laidlaw upped their price target on Affimed from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Wells Fargo & Company cut their price target on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday, April 1st. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research note on Monday, April 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Affimed in a research report on Thursday, June 13th.

Institutional Investors Weigh In On Affimed

Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its holdings in shares of Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares in the last quarter. Vestal Point Capital LP acquired a new stake in Affimed during the 4th quarter valued at $341,000. abrdn plc purchased a new position in Affimed during the fourth quarter worth $130,000. Finally, EWA LLC acquired a new position in shares of Affimed in the fourth quarter worth $89,000. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

Affimed Price Performance

Shares of NASDAQ AFMD opened at $5.45 on Tuesday. The business’s fifty day simple moving average is $5.50 and its 200-day simple moving average is $5.51. Affimed has a 12-month low of $2.23 and a 12-month high of $8.95. The company has a current ratio of 3.06, a quick ratio of 3.06 and a debt-to-equity ratio of 0.12.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.